Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Inclusion Criteria: * Able and willing to provide informed consent/assent and comply with protocol requirements * Documented diagnosis of either pheochromocytoma or paraganglioma that was confirmed by histology or other supportive data (e.g. abnormal MIBG diagnostic study or elevated tumor markers) * Ineligible for curative surgery for PPGL * Failed a prior therapy for PPGL or have no alternative indicated therapy available * Have definitive tumor avidity confirmed by the AZEDRA dosimetry dose * Life expectancy of at least 6 months per physician Exclusion Criteria: * Pregnant or nursing females * Men or women of childbearing potential and unwilling to use a medically acceptable form of contraception from time of consent until 6 months following last therapeutic dose of AZEDRA * Active CNS lesions by CT/MRI within 3 months of informed consent * NYHA class IV heart failure, unstable angina pectoris or clinically significant cardiac arrhythmia that poses a risk of syncope or cardiac arrest * Prior systemic radiotherapy resulting in marrow toxicity within 3 months of first AZEDRA therapeutic dose * Prior iobenguane I 131 therapeutic exposure within 12 weeks of the first planned therapeutic dose * Prior administration of whole-body radiation therapy within 12 weeks of the first planned therapeutic dose * Prior external beam radiotherapy to \> 25% of bone marrow * Prior chemotherapy or investigational compound and/or device within 30 days of the dosimetry dose * Other active mal…